Rates of Return in Diagnostics IPOs by Market Cap
This article was originally published in Start Up
Executive Summary
The rarest IPOs in recent months have been those in diagnostics, with only three completed so far this year. Nonetheless, we wondered how diagnostics companies that received the highest market caps in IPOs over the past two years fared against their smaller-cap counterparts on delivering rates of return to private investors.
You may also be interested in...
Vysis Preps For Prime Time
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
Cosmetic And Personal Care Trademark Review 7 December, 2021
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Plenity: A Device For Weight Loss that Looks Like A Drug, And Is Sold Like A Consumer Product
Medtech Insight spoke to the chief executive and chief operating officers of Plenity’s manufacturer, Gelesis, to learn more about its weight loss device.